B Symptoms in Lymphoma

Definition and Clinical Significance

The National Comprehensive Cancer Network defines B symptoms as a triad of constitutional symptoms consisting of unexplained fever >38°C, drenching night sweats, and weight loss >10% of body weight within 6 months prior to diagnosis 1, 2
The presence or absence of B symptoms is a critical staging modifier in Hodgkin lymphoma, dividing each Ann Arbor stage into "A" (no systemic symptoms) or "B" (B symptoms present) 1, 2

B symptoms are more common in patients with HIV-associated Hodgkin lymphoma and should always prompt investigation for opportunistic infections in this population 3
In people living with HIV, approximately 90% of Hodgkin lymphoma cases are Epstein-Barr virus (EBV)-associated, and these patients more commonly present with advanced disease, extranodal involvement, and B symptoms 3

The presence of B symptoms is an unfavorable prognostic factor that influences treatment decisions in early-stage disease 1, 4
Patients with stage I-II disease and B symptoms are classified as "early-stage unfavorable" rather than "early-stage favorable," which affects the intensity and duration of therapy 1, 4

The National Comprehensive Cancer Network classifies early-stage disease as "early favorable" (Stage I-II without B symptoms or other unfavorable factors) or "early unfavorable" (Stage I-II with B symptoms or other risk factors) 1, 4
Advanced stage disease is classified as Stage III-IV, where B symptoms contribute to the International Prognostic Score 1

The National Comprehensive Cancer Network recommends not confusing B symptoms with other causes of fever, night sweats, or weight loss—particularly infectious etiologies in immunocompromised patients 3
In patients with HIV or other immunosuppression, an infectious disease workup should be performed when B symptoms are present, as opportunistic infections can mimic lymphoma presentation 3

The NCCN advises that any patient presenting with B symptoms (including fever) should first be evaluated for opportunistic infections before attributing the findings solely to Hodgkin lymphoma, especially in immunocompromised individuals. [5][6]
For HIV‑positive patients, the NCCN emphasizes that B symptoms must trigger a work‑up for opportunistic infections because approximately 90 % of Hodgkin lymphoma cases in this population are associated with Epstein‑Barr virus. [5][6]

The NCCN designates ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) as the standard first‑line chemotherapy regimen for Hodgkin lymphoma, with dose or drug modifications based on disease stage and individual risk factors. 5

In HIV‑positive patients with Hodgkin lymphoma who develop fever, the NCCN recommends the use of hematopoietic growth factors when CD4‑positive lymphocyte counts are low, despite potential concerns about bleomycin‑related toxicity. [5][6]
The NCCN suggests initiating prophylactic antibiotics targeting gram‑negative organisms and Pneumocystis jirovecii pneumonia (PJP) when CD4‑positive lymphocyte counts fall below 200 cells/µL. [5][6]